We take pride in our Corporate Social Responsibility (CSR) activities. These are activities that transcend short-term focus on profits and address greater societal need.
SARS-COV2 (COVID19) protein structure - FDA active compound simulation
We have simulated 1513 FDA approved active compounds against 11 published SARS-COV2 (COVID-19) protein structures to see if an existing compound can affect viral protein assembly and/or activity. MGHPCC recently wrote about this work here. As of December 2020 we have access to over 1.5MM detailed de-identified patient records to further our COVID-19 research.
04-06-2021: The detailed pre-print manuscript is here.
Convalescent plasma effectiveness against COVID-19
From December 2020 we have been leading a team of multi-institution researchers to assess where convalescent plasma is an effective treatment for hospitalized COVID-19 patients. Our results will be based on 2.5MM de-identified patient dataset from NIH/N3C.
04-07-2020: The analysis is complete and we expect to imminently release our results.